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Aging can be viewed as a progressive decline in the function of cells, tissues, and organs. The molecular basis underlying aging and age‐related degenerative changes remains unclear[1](#jor23409-bib-0001){ref-type="ref"}; however, it is believed that these changes are driven by time‐dependent accumulation of stochastic molecular and cellular damage.[1](#jor23409-bib-0001){ref-type="ref"}, [2](#jor23409-bib-0002){ref-type="ref"} Consistent with this theory, the majority of human progeroid syndromes, or diseases of accelerated aging, are caused by defects in mechanisms required for genome maintenance.[3](#jor23409-bib-0003){ref-type="ref"} This suggests that DNA damage is one type of stochastic molecular instability that promotes age‐related degenerative changes.

Murine models of progeroid syndromes have been studied extensively, with the aim of elucidating the relationship between DNA damage and age‐related functional decline. Excision repair cross‐complementation group 1 (ERCC1) and xeroderma pigmentosum complementation group F (XPF) form a heterodimeric endonuclease that is required for numerous DNA repair mechanisms.[4](#jor23409-bib-0004){ref-type="ref"}, [5](#jor23409-bib-0005){ref-type="ref"} XPF encodes the catalytic subunit of the endonuclease, while ERCC1 serves as an essential binding partner that enables the repair of damaged DNA.[6](#jor23409-bib-0006){ref-type="ref"} Reduced expression of XPF due to a mutation in the *XPF* gene causes XFE progeroid syndrome.[7](#jor23409-bib-0007){ref-type="ref"} This was recapitulated in the mouse by a mutation of the *mErcc1* locus to titrate the expression of ERCC1‐XPF.[8](#jor23409-bib-0008){ref-type="ref"} *Ercc1* ^−/Δ^ mice, harboring one knock‐out and one hypomorphic allele of *Ercc1*, express 5--10% of the normal level of the nuclease and have a maximum lifespan of 28 weeks.[9](#jor23409-bib-0009){ref-type="ref"} These mice demonstrate spontaneous and premature onset of age‐related changes in the epidermal, hematopoietic, endocrine, hepatobiliary, renal, nervous, and musculoskeletal systems, identical to XFE progeroid syndrome.[9](#jor23409-bib-0009){ref-type="ref"}, [10](#jor23409-bib-0010){ref-type="ref"}, [11](#jor23409-bib-0011){ref-type="ref"}, [12](#jor23409-bib-0012){ref-type="ref"}, [13](#jor23409-bib-0013){ref-type="ref"} In addition, the alterations in histopathology, pathophysiology, and genome‐wide transcriptional reprogramming observed in this animal model correlate with those observed in naturally aged mice.[14](#jor23409-bib-0014){ref-type="ref"}

Muscle‐derived stem/progenitor cells (MDSPCs) are multipotent cells isolated from postnatal skeletal muscle through an established preplate technique.[15](#jor23409-bib-0015){ref-type="ref"}, [16](#jor23409-bib-0016){ref-type="ref"}, [17](#jor23409-bib-0017){ref-type="ref"} They exhibit many important stem cell characteristics including long‐term proliferation, resistance to oxidative and inflammatory stresses, multi‐lineage differentiation, and self‐renewal capacities. MDSPCs can improve the regeneration of bone, and skeletal and cardiac muscle, mainly through the induction of neovascularization.[15](#jor23409-bib-0015){ref-type="ref"}, [18](#jor23409-bib-0018){ref-type="ref"}, [19](#jor23409-bib-0019){ref-type="ref"}, [20](#jor23409-bib-0020){ref-type="ref"} A recent study demonstrated that cell proliferation and multi‐lineage differentiation of MDSPCs isolated from progeroid *Ercc1* ^−/Δ^ mice were comparable to those of MDSPCs isolated from old WT mice, but considerably impaired relative to those of MDSPCs isolated from young‐WT mice.[21](#jor23409-bib-0021){ref-type="ref"} Furthermore, fewer cells expressing stem/progenitor cell markers were found in the skeletal muscle of these progeroid mice compared to young‐WT mice.[21](#jor23409-bib-0021){ref-type="ref"} The reduction in number and increased dysfunction of MDSPCs contributes to age‐related loss of tissue function since the transplantation of functional young‐WT MDSPCs into progeroid mice extends their lifespan and healthspan.[21](#jor23409-bib-0021){ref-type="ref"} This is also the case with naturally aged normal rodents; transplantation of mesenchymal stem cells extends the health and lifespan of old rats.[22](#jor23409-bib-0022){ref-type="ref"}

It has been proposed that the mammalian target of rapamycin (mTOR) signaling pathways play a role in the progression of aging,[23](#jor23409-bib-0023){ref-type="ref"} and it has been shown that inhibiting mTOR in yeast, worms, and flies extends their life‐spans.[24](#jor23409-bib-0024){ref-type="ref"}, [25](#jor23409-bib-0025){ref-type="ref"} Notably, rapamycin, an inhibitor of mTOR, administered at a late stage in the life of genetically heterogeneous mice, significantly extends their lifespan.[26](#jor23409-bib-0026){ref-type="ref"} Downstream factors in the mTOR pathway including the 70‐kDa ribosomal protein S6 kinase (*p*70S6K) and eIF4‐Ebinding protein 1 (4E‐BP1) bind to mRNA and regulate translation, thereby controlling the rate of protein synthesis and consequently cell growth.[27](#jor23409-bib-0027){ref-type="ref"} Increased lifespan could also be explained by increased autophagy in response to mTOR inhibition. Autophagy is the controlled self‐degradation of damaged, redundant, or hazardous cellular components, ranging from individual proteins (microautophagy) to entire organelles (macroautophagy). Both protein synthesis and autophagy are considered to be critical in the regulation of lifespan by mTOR.[28](#jor23409-bib-0028){ref-type="ref"}

The purpose of this study was to determine if mTOR signaling also plays a role in stem cell dysfunction as it relates to aging. We hypothesized that inhibiting mTOR would rescue the defect, at least in part, in *Ercc1* ^−/Δ^ MDSPCs, and could represent a target to delay aging. Our study not only demonstrates a correlation between MDSPC dysfunction and mTOR activity, but also shows that exposing progeroid MDSPCs to rapamycin promoted myogenic differentiation, while attenuating apoptosis and cellular senescence.

MATERIALS AND METHODS {#jor23409-sec-0003}
=====================

Isolation of MDSPCs {#jor23409-sec-0004}
-------------------

All animal experiments were performed with the approval of the University of Pittsburgh\'s Institutional Animal Care and Use Committee. MDSPCs were isolated via a modified preplate technique, as previously described,[15](#jor23409-bib-0015){ref-type="ref"}, [16](#jor23409-bib-0016){ref-type="ref"}, [21](#jor23409-bib-0021){ref-type="ref"} from adult WT (19‐week‐old) and progeroid *Ercc1* ^−/Δ^ (19‐week‐old) mice (*n *= 4 per strain), which were bred at the University of Pittsburgh\'s Division of Laboratory Animal Research. MDSPCs were cultured in proliferation medium (PM), which contains Dulbecco\'s modified Eagle\'s medium (DMEM), 10% fetal bovine serum (FBS), 10% horse serum, 1% penicillin/streptomycin (all from Invitrogen,, Waltham, MA), and 0.5% chick embryo extract (Accurate Chemical and Scientific Corporation, Westbury, NY). The isolated MDSPCs were plated on collagen type I‐coated 25 cm^2^ flasks at a density of 3 × 10^5^ cells per well in PM. At 70% confluence, the cells were dissociated with trypsin/EDTA, replated at a cell density of 1.0--2.5 × 10^3^ cells/cm^2^, and cultured for 3--4 weeks before performing the cell treatments described below.

Rapamycin Treatment {#jor23409-sec-0005}
-------------------

Rapamycin was obtained from LC Laboratories (Woburn, MA), dissolved in dimethyl sulphoxide (DMSO) at 50 mg/ml, and stored at −20°C. MDSPCs from *Ercc1* ^−/Δ^ and WT mice were treated with 10 nM rapamycin in order to inhibit mTOR. As a control, the same amount of DMSO was used to treat MDSPCs from these two populations.

Proliferation Assay {#jor23409-sec-0006}
-------------------

MDSPCs were plated on collagen type I‐coated 25 cm^2^ flasks at a density of 2,000 cells per well. Live‐cell imaging was performed using an imaging system equipped with a 20× objective lens (Automated Cell Technologies, Pittsburgh, PA). Images were obtained at 10 min intervals over a period of 72 h, and 10 of these images were randomly selected for analysis at four separate time points during the experiment (0, 24, 48, and 72 h).

Apoptosis Assay {#jor23409-sec-0007}
---------------

Apoptotic cell death was evaluated in cultured cells using the In situ Cell Death Detection kit containing fluorescein (Roche Applied Science, Penzberg, Germany) for TUNEL detection according to the manufacturer\'s protocol. To visualize the nuclei, the cultures were incubated with 4′,6‐diamidino‐2‐phenylindole (DAPI) for 10 min. The presence of fluorescein as a cell death marker was visualized using a Leica DMIRB microscope. The number of cells that were TUNEL‐positive was calculated and averaged across 15 fields each from three replicate plates for each of four independent experiments. The percentage of apoptotic cells was calculated as TUNEL‐positive cells divided by the total number of cells, and then multiplied by 100.

Cellular Senescence Assay {#jor23409-sec-0008}
-------------------------

Cellular senescence was evaluated in cultured cells using a Senescence β‐Galactosidase Staining Kit (Cell Signaling Technology, Danvers, MA) to measure SA‐β‐gal activity, according to the manufacturer\'s protocol. Images were captured using a Leica DMIRB microscope. The number of cells that were SA‐β‐gal‐positive was calculated and averaged across 15 fields each from three replicate plates for each of four independent experiments. The percentage of senescent cells was calculated as SA‐β‐gal‐positive cells divided by the total number of cells and then multiplied by 100.

Myogenic Differentiation Assay {#jor23409-sec-0009}
------------------------------

MDSPCs were plated in PM at a density of 1,000 cells/cm^2^ and cultured for 3 days. The cells were then placed in DMEM supplemented with 2% FBS for an additional 4 days to induce myogenic differentiation, as described previously,[21](#jor23409-bib-0021){ref-type="ref"} with or without 10 nM rapamycin. On day 7, immunostaining was performed to detect fast myosin heavy chain (f‐MyHC) expression, a marker of terminal myogenic differentiation. Cold methanol‐fixed cultures were blocked with 5% goat serum and incubated with f‐MyHC mouse monoclonal antibody (1:250; Sigma--Aldrich, St. Louis, MO), secondary biotinylated IgG (1:250; Vector Laboratories, Burlingame, CA) for 1 h, and streptavidin‐594 (1:500; Sigma--Aldrich) for 15 min to fluorescently label the myotubes. Nuclei were counter stained with DAPI (100 ng/ml; Sigma--Aldrich) for 10 min. The presence of fluorescein was visualized using a Leica DMIRB microscope equipped with a Retiga digital camera and evaluated using Northern Eclipse software (v. 6.0; Empix Imaging). Myogenic differentiation was calculated as the percentage of cells expressing f‐MyHC. Data from three replicate plates from each of four independent experiments were analyzed. Total RNA was also extracted as described below for quantitative reverse transcription polymerase chain reaction (qRT‐PCR) analysis. Expression of the myogenic genes *MyHC* and *Desmin* were also analyzed.

SDS--PAGE and Immunoblotting {#jor23409-sec-0010}
----------------------------

Cells were lyzed in Laemmli Sample Buffer (Bio‐Rad Laboratories, Hercules, CA), boiled for 5 min, and centrifuged at 4,000 rpm for 5 min. The samples were loaded on a 4--12% SDS--polyacrylamide gel, transferred to an Immobilon polyvinyl difluoride (PVDF) transfer membrane (Merck Millipore, Billerica, MA) and probed with primary antibodies followed by horseradish peroxidase (HRP)‐conjugated secondary antibody. Proteins were visualized with ECL Plus reagent (GE Healthcare, Chicago, IL), and the chemical luminescent reaction visualized using a FOTO/Analyst Luminary/Fx CCD imaging system (Fotodyne, Inc., Hartland, WI). The following antibodies were used in this study: Rabbit anti‐mTOR, rabbit anti‐phospho‐mTOR (*p*‐mTOR), rabbit anti‐phospho‐4E‐BP1 (*p*‐4E‐BP1) (Thr37/46), rabbit anti‐phospho‐p70‐S6 (*p*‐*p*70‐S6) kinase (Thr389), rabbit anti‐LC3, rabbit anti‐poly (ADP‐ribose) polymerase (PARP), rabbit anti‐*p*16, rabbit anti‐*p*21, rabbit anti‐glyceraldehyde phosphate dehydrogenase (GAPDH), HRP‐conjugated goat anti‐rabbit IgG, and HRP‐conjugated goat anti‐mouse IgG (all antibodies were from Cell Signaling Technology). The intensities of the bands were quantified using image analysis software, ImageJ version (NIH Image). Values were normalized relative to GAPDH expressions.

RNA Isolation and Quantitative RT‐PCR {#jor23409-sec-0011}
-------------------------------------

Total RNA was extracted using the QIAshredder homogenizer and the RNeasy Mini kit (Qiagen; Venlo, Netherlands) according to the manufacturer\'s protocol. One microgram of total RNA was used for random hexamer‐primed cDNA synthesis using a Super Script II pre‐amplification system (Invitrogen). Quantitative RT‐PCR reactions were performed in triplicate using iQ5 (Bio‐Rad) and Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific, Waltham, MA) and 300 nM of each of the primers. The primers were designed based on the sequences in the GenBank database. The primer pairs used for this study are shown in Table [1](#jor23409-tbl-0001){ref-type="table-wrap"}. Electrophoretic separation on a 2.5% agarose gel was performed to ensure accurate outcomes of the reactions.

###### 

Primer Sequences and Product Side for Real‐Time PCR

  Gene                                      5′ DNA Sequence 3′           Amplicon Length (bp)
  ---------- ------------------------------ ---------------------------- ----------------------
  *MyHC*     Forward                        5′‐CCAGGCTGCGGAGGCAATCA‐3′   115
  Reverse    5′‐GGCCAGCTGCTCTTTCAGGTCG‐3′                                
  *Desmin*   Forward                        5′‐TTCCCTCGAGCAGGCTTCGG‐3′   147
  Reverse    5′‐GCCATAGGATGGCGCTCGGG‐3′                                  
  *GAPDH*    Forward                        5′‐CCGTCGTGGATCTGACGTG‐3′    146
  Reverse    5′‐GTTGCTGTTGAAGTCGCAGG‐3′                                  
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Statistical Analysis {#jor23409-sec-0012}
--------------------

The data were expressed as the mean ± standard deviation (SD). For multiple comparisons, one‐way ANOVA or the Kruskal--Wallis tests were applied. Pair‐wise multiple comparisons were performed using the Tukey--Kramer or Scheffe\'s post hoc test. Data analyses were performed using PASW Statistics 21 (SPSS, Chicago, IL). Statistical significance was accepted at *p *\< 0.05.

RESULTS {#jor23409-sec-0013}
=======

mTOR Signaling Is Elevated in MDSPCs Isolated From Progeroid *Ercc1* ^−/Δ^ Mice {#jor23409-sec-0014}
-------------------------------------------------------------------------------

To test the hypothesis that mTOR signaling contributes to the age‐related dysfunction seen in MDSPCs isolated from progeroid *Ercc1* ^−/Δ^ mice, the phosphorylation of downstream signaling components of the mTOR pathway was examined by immunoblotting (Fig. [1](#jor23409-fig-0001){ref-type="fig"}A). The expression of *p*‐mTOR, *p*‐4E‐BP1, and *p*‐*p*70‐S6 kinase in *Ercc1* ^−/Δ^ MDSPCs was increased compared with WT MDSPCs (p‐mTOR: *p *\< 0.001, *p*‐4E‐BP1: *p *\< 0.001, *p*‐*p*7‐S6: *p *\< 0.001). Rapamycin treatment significantly decreased the expression of p‐mTOR and p‐p70‐S6 kinase in *Ercc1* ^−/Δ^ MDSPCs (p‐mTOR: *p *\< 0.001, *p*‐*p*7‐S6: *p *\< 0.001). However, p‐4E‐BP1 was not significantly reduced upon rapamycin treatment (*p* = 0.506) (Fig. [1](#jor23409-fig-0001){ref-type="fig"}B). Of note, rapamycin had no significant effect on the baseline activity of mTOR in WT MDSPCs.

![Measuring mTOR activity and autophagy in MDSPCs isolated from progeroid *Ercc1* ^−/Δ^ mice. (A) Shown is a representative image of immunoblotting to measure mTOR, p‐mTOR, *p*‐4E‐BP1, and *p*‐*p*70 S6 expression in MDSPCs isolated from *Ercc1* ^−/Δ^ and WT mice cultured with and without rapamycin. (B) Quantification of p‐mTOR, *p*‐4E‐BP1, and p‐p70 S6 expression relative to GAPDH. Error bars indicate the standard deviation. Statistical significance was determined using one‐way ANOVA or the Kruskal--Wallis test with Tukey--Kramer or Scheffe\'s post hoc test (*n* = 4). ^\#\#\#^ *p *\< 0.001 versus WT‐DMSO, \*\*\**p *\< 0.001 versus *ERCC1* ^−/Δ^‐DMSO. (C) Representative image of immunoblotting to measure autophagy markers LC3 I and II expression in MDSPCs isolated from *Ercc1* ^−/Δ^ and WT mice cultured with and without rapamycin. (D) Quantification of LC3II expression relative to GAPDH expression. Error bars indicate the standard deviation. Statistical significance was determined using the Kruskal--Wallis test with Scheffe\'s post hoc test (*n* = 4). ^\#\#\#^ *p *\< 0.001 versus WT‐DMSO, \*\*\**p *\< 0.001 versus *Ercc1* ^−/Δ^‐DMSO. (E) Proliferation of MDSPCs measured using live‐cell imaging. Error bars indicate the standard deviation. Statistical significance was determined using one‐way ANOVA with Tukey--Kramer post hoc test (*n* = 4). ^\#\#\#^ *p *\< 0.001 versus WT‐DMSO.](JOR-35-1375-g001){#jor23409-fig-0001}

Rapamycin Increases Autophagy in MDSPCs Isolated From Progeroid *Ercc1* ^−/Δ^ Mice {#jor23409-sec-0015}
----------------------------------------------------------------------------------

Recent studies have provided evidence that a decline in autophagy, which is regulated by mTOR, contributes to aging.[29](#jor23409-bib-0029){ref-type="ref"}, [30](#jor23409-bib-0030){ref-type="ref"} We next measured LC3 expression, which correlates with autophagic activity.[31](#jor23409-bib-0031){ref-type="ref"} Immunoblotting analysis revealed that the amount of LC3‐II was significantly lower in *Ercc1* ^−/Δ^ MDSPCs compared to WT MDSPCs (*p *\< 0.001) (Fig. [1](#jor23409-fig-0001){ref-type="fig"}C and D). Treatment with rapamycin significantly increased the amount of LC3‐II in the *Ercc1* ^−/Δ^ MDSPC population (*p *\< 0.001) (Fig. [1](#jor23409-fig-0001){ref-type="fig"}D).

Rapamycin Increases the Proliferation Capacity of MDSPCs From Progeroid Mice {#jor23409-sec-0016}
----------------------------------------------------------------------------

Proliferation of MDSPCs, measured by live cell imaging, was significantly lower in isolates from *Ercc1* ^−/Δ^ mice, compared to MDSPCs from WT mice, at both 48 and 72 h (*p *\< 0.001). Treatment of the cells with rapamycin had no effect on the proliferation capacity of MDSPCs of either genotype (Fig. [1](#jor23409-fig-0001){ref-type="fig"}E).

Rapamycin Decreases Apoptosis of MDSPCs From Progeroid Mice {#jor23409-sec-0017}
-----------------------------------------------------------

Some adult stem cell populations are dramatically affected by stress, leading to increased apoptosis.[32](#jor23409-bib-0032){ref-type="ref"} We next determined the level of apoptosis in MDSPCs using the TUNEL assay. The percent of TUNEL‐positive cells was significantly higher among *Ercc1* ^−/Δ^ MDSPCs than among WT MDSPCs (*p *\< 0.001) (Fig. [2](#jor23409-fig-0002){ref-type="fig"}A and B). Rapamycin treatment significantly (*p* \< 0.001) reduced the percentage of TUNEL‐positive cells among *Ercc1* ^−/Δ^ MDSPCs (Fig. [2](#jor23409-fig-0002){ref-type="fig"}B). Furthermore, an increase in the expression of cleaved PARP (apoptosis marker) was detected in MDSPCs from progeroid *Ercc1* ^−/Δ^ mice relative to WT MDSPCs, and rapamycin treatment of the cells attenuated the expression of this apoptotic marker (Fig. [2](#jor23409-fig-0002){ref-type="fig"}C).

![Measuring the effect of rapamycin on apoptosis in MDSPCs isolated from progeroid *Ercc1* ^−/Δ^ mice. (A) Representative images of TUNEL assay. Live cells (DAPI: blue), apoptotic cells (yellow--green), and merged figures. Scale bar = 100 µm. (B) The percentage of TUNEL‐positive cells was counted from images obtained from four independent MDSPC populations per genotype and treatment group. Error bars indicate the standard deviation. ^\#\#\#^ *p *\< 0.001 versus WT‐DMSO, \*\*\**p *\< 0.001 versus *ERCC1* ^−/Δ^‐DMSO. Statistical significance was determined using the Kruskal--Wallis test with Scheffe\'s post hoc test. (C) Immunoblotting to measure the expression of cleaved PARP, an apoptosis‐related marker, in MDSPCs isolated from *Ercc1* ^−/Δ^ and WT mice cultured with and without rapamycin.](JOR-35-1375-g002){#jor23409-fig-0002}

Rapamycin Decreases Premature Senescence of MDSPCs From Progeroid Mice {#jor23409-sec-0018}
----------------------------------------------------------------------

Cellular senescence is characterized by cell cycle arrest, which leads to an irreversible loss of the self‐renewal and differentiation capacities of stem cells.[33](#jor23409-bib-0033){ref-type="ref"} To determine the extent of senescence in MDSPCs isolated from *Ercc1* ^−/Δ^ mice, senescence‐associated beta‐galactosidase (SA‐β‐gal) activity was measured. The percentage of SA‐β‐gal‐positive cells was significantly higher in *Ercc1* ^−/Δ^ MDSPCs than in WT MDSPCs (*p *\< 0.001) (Fig. [3](#jor23409-fig-0003){ref-type="fig"}A). However, rapamycin treatment reduced the percentage of SA‐β‐gal‐positive *Ercc1* ^−/Δ^ MDSPCs (*p *\< 0.001) (Fig. [3](#jor23409-fig-0003){ref-type="fig"}A). Moreover, increased expression of *p*16 and *p*21 were detected in the progeroid *Ercc1* ^−/Δ^ MDSPCs compared to WT MDSPCs, and rapamycin treatment resulted in the lowered expression of these cell senescence markers in *Ercc1* ^−/Δ^ MDSPCs (Fig. [3](#jor23409-fig-0003){ref-type="fig"}B).

![Measuring the effect of rapamycin on senescence in MDSPCs isolated from progeroid *Ercc1* ^−/Δ^ mice. (A) The histogram indicates the percent of SA β‐gal‐positive cells from four independent MDSPC populations from each genotype and treatment group. Error bars indicate the standard deviation. ^\#\#\#^ *p *\< 0.001 versus WT‐DMSO, \*\*\**p *\< 0.001 versus *Ercc1* ^−/Δ^‐DMSO. Statistical significance was determined using one‐way ANOVA test with Scheffe\'s post hoc test. (B) Immunoblotting to measure the expression of senescence‐related markers *p*16 and *p*21 in MDSPCs isolated from *Ercc1* ^−/Δ^ and WT mice cultured with and without rapamycin.](JOR-35-1375-g003){#jor23409-fig-0003}

Rapamycin Improves the Myogenic Differentiation Capacity of MDSPCs From Progeroid Mice {#jor23409-sec-0019}
--------------------------------------------------------------------------------------

To determine whether the myogenic differentiation capacity of MDSPCs isolated from progeroid *Ercc1* ^−/Δ^ mice is affected by mTOR signaling, the cells were cultured to confluence and then switched to differentiation medium. In the presence or absence of rapamycin, WT MDSPCs fused to form multinucleated myotubes expressing f‐MyHC, a marker of terminal myogenic differentiation (Fig. [4](#jor23409-fig-0004){ref-type="fig"}A and B). In contrast, cultures of MDSPCs isolated from the progeroid *Ercc1* ^−/Δ^ mice had significantly fewer f‐MyHC expressing cells, indicating an impairment in their differentiation capacity (*p *\< 0.001) (Fig. [4](#jor23409-fig-0004){ref-type="fig"}B). Interestingly, rapamycin significantly improved the myogenic differentiation capacity of the *Ercc1* ^−/Δ^ MDSPCs (*p *\< 0.001) (Fig. [4](#jor23409-fig-0004){ref-type="fig"}A and B). Impaired differentiation of *Ercc1* ^−/Δ^ MDSPCs was confirmed by measuring the expression of the myogenic differentiation markers myosin heavy chain (MyHC) and desmin. The expression levels of MyHC and desmin were significantly lower in MDSPCs isolated from the progeroid mice than in WT MDSPCs (MyHC: *p *\< 0.001, desmin: *p *\< 0.001). The expression levels of both proteins were increased upon rapamycin treatment (MyHC: *p *\< 0.001, desmin: *p* = 0.002, respectively) (Fig. [4](#jor23409-fig-0004){ref-type="fig"}C and D).

![Measuring the effect of rapamycin on the myogenic differentiation of MDSPCs isolated from progeroid *Ercc1* ^−/Δ^ mice. (A) Images of in vitro myogenic differentiation. Cells were immunostained for the terminal differentiation marker, f‐MyHC (red). Scale bar = 50 µm. (B) Quantification of myogenic differentiation was calculated as the fraction of cells (DAPI, blue) expressing f‐MyHC (red) from four independent MDSPC populations. Error bars indicate the standard deviation. Statistical significance was determined using one‐way ANOVA test with Tukey--Kramer post hoc test. ^\#\#\#^ *p *\< 0.001 versus WT‐DMSO, \*\*\**p *\< 0.001 versus *Ercc1* ^−/Δ^‐DMSO. (C and D). Quantitative RT‐PCR to measure the expression levels of the myogenic differentiation markers MyHC and desmin after myogenic differentiation of MDSPCs isolated from *Ercc1* ^−/Δ^ and WT mice, cultured with and without rapamycin. Error bars indicate the standard deviation. Statistical significance was determined using one‐way ANOVA test with Tukey--Kramer or Scheffe\'s post hoc test (*n* = 4). ^\#\#\#^ *p *\< 0.001 versus WT‐DMSO, \*\**p *\< 0.01, \*\*\**p *\< 0.001 versus *Ercc1* ^−/Δ^‐DMSO.](JOR-35-1375-g004){#jor23409-fig-0004}

DISCUSSION {#jor23409-sec-0020}
==========

In this study, we examined the role that mTOR plays in the myogenic differentiation, apoptosis, and senescence of MDSPCs isolated from a murine model of a human progeroid syndrome. Previous studies established that the cell proliferation and myogenic differentiation capacities of MDSPCs isolated from progeroid *Ercc1* ^−/Δ^ mice are similar to MDSPCs isolated from naturally aged mice and were significantly impaired relative to that of MDSPCs isolated from young‐WT mice.[21](#jor23409-bib-0021){ref-type="ref"} Furthermore, fewer cells expressing stem/progenitor cell markers could be isolated from the skeletal muscle of these progeroid *Ercc1* ^−/Δ^ mice than from young‐WT mice.[21](#jor23409-bib-0021){ref-type="ref"} Here, we demonstrate that MDSPCs isolated from this murine model of accelerated aging exhibit increased mTOR expression and a reduction in autophagy. Inhibiting mTOR in this adult stem cell population improved the myogenic capacity of the progeroid MDSPCs.

mTOR is a protein kinase that helps to integrate cellular activities in response to nutrients, stress, and extra‐cellular signals, including hormones and locally produced growth factors.[34](#jor23409-bib-0034){ref-type="ref"} The mTOR signaling pathways play multiple roles in adult animals that are involved in cell growth, aging, cancer, and metabolic disorders.[35](#jor23409-bib-0035){ref-type="ref"} Hyperactivation of mTOR signaling has been reported in the cardiac and skeletal muscles of progeroid *Lmna^−/−^* mice.[36](#jor23409-bib-0036){ref-type="ref"} In accordance with these observations, hematopoietic stem cells (HSCs) from old mice have elevated mTOR activity, and increasing mTOR signaling in young mice induces premature aging.[37](#jor23409-bib-0037){ref-type="ref"} Here, we show that mTOR activity is higher in MDSPCs isolated from progeroid mice than in WT MDSPCs (Fig. [1](#jor23409-fig-0001){ref-type="fig"}). These observations suggest that abnormally increased activation of the mTOR pathway could be involved in stem cell exhaustion/depletion, which has been linked with an accelerated aging phenotype.[38](#jor23409-bib-0038){ref-type="ref"}

mTOR regulates protein synthesis through the phosphorylation of 4E‐BP1 and *p*70‐S6.[27](#jor23409-bib-0027){ref-type="ref"} Our results demonstrate that the phosphorylation of 4E‐BP1 and *p*70‐S6 is increased in MDSPCs isolated from progeroid mice, and that the phosphorylation of *p*70‐S6 is decreased following treatment with rapamycin. However, phosphorylation of the mTOR target 4E‐BP1 does not change significantly following rapamycin treatment. Consistent with our findings, previous studies have reported that rapamycin has a greater effect on *p*70‐S6 kinase phosphorylation than on 4E‐BP1 phosphorylation.[39](#jor23409-bib-0039){ref-type="ref"} *p*70‐S6 is among the major downstream targets of the mTOR pathway; deletion of the *p*70‐S6 gene increases lifespan in mice[40](#jor23409-bib-0040){ref-type="ref"} and retards the aging of bone, the immune system, and skeletal muscle.[41](#jor23409-bib-0041){ref-type="ref"}

Another important function of the mTOR signaling pathway is the regulation of autophagy, a process in which the cell degrades damaged or excess cellular components, ranging from individual proteins and protein aggregates to whole organelles, through the lysosomal machinery of the cell. Recent studies have provided evidence that insufficient autophagy is implicated in normal aging.[29](#jor23409-bib-0029){ref-type="ref"}, [30](#jor23409-bib-0030){ref-type="ref"}, [42](#jor23409-bib-0042){ref-type="ref"}, [43](#jor23409-bib-0043){ref-type="ref"} Stem cells lose their capacity to self‐renew and differentiate when autophagy is disrupted; hence, the cells essentially lose their "stemness."[44](#jor23409-bib-0044){ref-type="ref"} Interestingly, rapamycin treatment activates the clearance of progerin and consequently slows down the accelerated aging process.[45](#jor23409-bib-0045){ref-type="ref"} In MDSPCs from progeroid *Ercc1* ^−/Δ^ mice, autophagy is significantly impaired relative to MDSPCs isolated from WT mice, but significantly increased in the presence of rapamycin. Therefore, it is possible that the loss of the differentiation potential of the MDSPCs is partially due to insufficient autophagy.

MDSPCs isolated from progeroid *Ercc1* ^−/Δ^ mice have significantly fewer f‐MyHC expressing cells, consistent with their reduced myogenic differentiation capacity. However, inhibition of mTOR using rapamycin restores, at least in part, the myogenic differentiation capacity of MDSPCs. These results suggest that autophagy plays a crucial role in differentiation by regulating the efficient removal of sets of transcription factors, enzymes, adhesion molecules, or secreted factors.[46](#jor23409-bib-0046){ref-type="ref"} Recent studies reported that the inhibition of mTOR with rapamycin triggers a negative feedback loop that results in the activation of Akt signaling.[47](#jor23409-bib-0047){ref-type="ref"}, [48](#jor23409-bib-0048){ref-type="ref"}, [49](#jor23409-bib-0049){ref-type="ref"} Sandri et al. demonstrated that phosphoinositide 3 (PI‐3) kinase‐Akt signaling inhibits Forkhead box O (Foxo) and atrogin‐1 expression, which causes atrophy of myotubes and muscle fibers.[50](#jor23409-bib-0050){ref-type="ref"} Akt signaling in skeletal muscle increases the production of MyHC isoforms and improves muscle mass and function.[51](#jor23409-bib-0051){ref-type="ref"}

Apoptosis and senescence are well‐documented cellular responses to DNA damage.[52](#jor23409-bib-0052){ref-type="ref"}, [53](#jor23409-bib-0053){ref-type="ref"} MDSPCs isolated from progeroid *Ercc1* ^−/Δ^ mice display significantly greater amounts of apoptosis and cellular senescence compared to MDSPCs isolated from WT mice. This finding is consistent with previous studies in which cells isolated from progeroid *Ercc1* ^−/Δ^ mice showed higher rates of apoptosis and cellular senescence.[11](#jor23409-bib-0011){ref-type="ref"}, [54](#jor23409-bib-0054){ref-type="ref"} The apoptosis and senescence of MDSPCs isolated from progeroid mice are reduced when mTOR is inhibited with rapamycin. Hence, the decreased capacity for myogenic differentiation of MDSPCs could be due in part to an increase in the levels of apoptosis and cellular senescence.[55](#jor23409-bib-0055){ref-type="ref"} The proliferation ability of *Ercc1* ^−/Δ^ MDSPCs was significantly lower than that of WT‐MDSPCs, a result similar to that of a previous study from our laboratory.[21](#jor23409-bib-0021){ref-type="ref"} However, rapamycin did not appear to influence the proliferation capacity of *Ercc1* ^−/Δ^ MDSPCs (Fig. [1](#jor23409-fig-0001){ref-type="fig"}E).

This study has several limitations that should be noted. First, we did not evaluate the effects of rapamycin treatment using an in vivo model. We would like to pursue this line of in vivo research in the future, but it is clear that the dosage and timing of rapamycin treatment will need to be optimized prior to determining the effect of rapamycin on the accelerated aging phenotype displayed by *Ercc1* ^−/Δ^ mice. Second, we did not evaluate the effects of rapamycin treatment on the osteogenic differentiation capacities of *Ercc1* ^−/Δ^ MDSPCs. In terms of age‐related functional decline, it is well known that reduced bone mineral density is a common feature of the aging skeleton. In a previous study, we showed that MDSPCs from *Ercc1* ^−/Δ^ mice have limited osteogenic potential.[21](#jor23409-bib-0021){ref-type="ref"} The effect of rapamycin on the multi‐lineage differentiation potential of MDSPCs beyond myogenesis requires further investigation. Finally, musculoskeletal tissues are highly adaptable and many signaling pathways, such as Akt signaling and Wnt signaling, among others, regulate muscle remodeling; therefore, the implication of these signaling pathways on the beneficial effect of rapamycin on progeria MDSPCs remains to be elucidated.

In conclusion, our results demonstrate that inhibiting mTOR with rapamycin improves the myogenic differentiation potentials of progeroid *Ercc1* ^−/Δ^ MDSPCs by decreasing the percentage of cells undergoing apoptosis, attenuating the rate of senescence, and promoting autophagy. The results from our current study provide novel insights into the spontaneous and premature onset of age‐related changes associated with progeria, and the role of mTOR on the accelerated aging of adult stem cells.
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